How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,785 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Ethnicity in Mycosis Fungoides: White patients present at an older age and with more advanced disease. (Abstract)

Ethnicity in Mycosis Fungoides: White patients present at an older age and with more advanced disease. 30604865 2019 01 28 1365-2133 2019 Jan 03 The British journal of dermatology Br. J. Dermatol. Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease. 10.1111/bjd.17602 Scarisbrick J J JJ Department of Dermatology, Centre for Rare Diseases, University Hospital Birmingham, Birmingham, U.K. Quaglino P P Department of Dermatology, University Hospital

2019 British Journal of Dermatology

42. Understanding racial disparities in mycosis fungoides through international collaborative studies. (Abstract)

Understanding racial disparities in mycosis fungoides through international collaborative studies. 30604871 2019 01 25 1365-2133 2019 Jan 03 The British journal of dermatology Br. J. Dermatol. Understanding racial disparities in mycosis fungoides through international collaborative studies. 10.1111/bjd.17598 Geller S S https://orcid.org/0000-0003-1206-1057 Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, U.S.A

2019 British Journal of Dermatology

43. Ingenol mebutate for mycosis fungoides. (Abstract)

Ingenol mebutate for mycosis fungoides. Ingenol mebutate is a macrocyclic diterpene ester, naturally found in the sap of the Australian plant Euphorbia peplus, which proved efficacious for actinic keratosis. In clinical routine, we observed local improvement of MF upon application of ingenol mebutate in MF patients treated for coincidental actinic keratosis within direct proximity of/overlapping with MF skin lesions. Hence, the objective of this study was to assess the effect of topical ingenol

2019 British Journal of Dermatology

44. Special Considerations in the Treatment of Mycosis Fungoides. (Abstract)

Special Considerations in the Treatment of Mycosis Fungoides. Mycosis fungoides is the most common form of cutaneous T cell lymphoma. Although normally presenting to physicians at an early stage and with an indolent course, mycosis fungoides can have a varied presentation. The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. Although comprehensive, in practice these guidelines do not provide specific treatment regimens (...) the possibility of side effects. Additionally, lesions located in the bathing suit distribution are often nonresponsive to first-line therapies for reasons still undetermined. Finally, although well-described, erythroderma secondary to mycosis fungoides is challenging to treat, with controversy surrounding various methods of control. This article both highlights difficult clinical scenarios and reviews the recommended treatment as provided by the NCCN guidelines and provides alternative therapy for lesions

2019 American journal of clinical dermatology

45. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. (Abstract)

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common cutaneous T-cell lymphomas. MF/SS is accompanied by considerable morbidity from pain, itching and disfigurement.To identify factors associated with poorer health-related quality of life (HRQoL) in newly diagnosed MF/SS patients.Patients

2019 British Journal of Dermatology

46. Advanced-stage Mycosis Fungoides. Role of STAT3, NFKB and NFAT pathways. (Abstract)

Advanced-stage Mycosis Fungoides. Role of STAT3, NFKB and NFAT pathways. The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are beginning to be identified. Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-MAPK, TCR-PLCG1-NFAT and JAK-STAT, may play an essential role in the pathogenesis of CTCL.We collected 100 samples that were submitted for diagnosis of, or a second opinion regarding mycosis fungoides

2019 British Journal of Dermatology

47. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome. Full Text available with Trip Pro

Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome. Tumor cells in cutaneous T cell lymphoma express limited numbers of chemokine receptors. We investigated the expression patterns of CXCR3, CCR3, CCR4 and CCR10 in mycosis fungoides, Sézary syndrome, lym-phomatoid papulosis and anaplastic large cell lymphoma in 121 skin biopsy samples. CXCR3 was expressed in 86% of mycosis fungoides cases but in no anaplastic large cell lymphoma cases. CCR3 (...) was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma. Mycosis fungoides/Sézary syndrome patients with high CCR3 or CCR4 expression had a poorer survival prognosis than mycosis fungoides/Sézary syndrome patients whose tumor cells did not express these receptors. CCR10 was expressed in 50% of mycosis fungoides/Sézary syndrome cases and in 13% of cases with CD30+ lym-phoproliferative disorders. These results suggest

2019 Acta Dermato-Venereologica

48. Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study. (Abstract)

Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study. Follicular mucinosis (FM), defined by mucin accumulation within follicular epithelium, may occur in mycosis fungoides (MF). FM without MF is occasionally reported in systemic hematologic malignancies, and may be diagnostically challenging.To describe clinicopathological characteristics of FM in patients with hematologic malignancies other than MF.Clinical data

2019 Journal of American Academy of Dermatology

49. Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients. (Abstract)

Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients. Mycosis fungoides (MF) typically has a CD4+ CD8- T-cell phenotype. Rare cases of CD4- CD8+ , CD4- CD8- , or CD4+ CD8+ immunophenotypes have been described. Little is known about the impact of MF immunophenotypes on disease behavior.We conducted a retrospective cohort study to review all cases of MF from 2007 to 2017 from Sunnybrook Health Sciences Centre, Toronto, Canada. CD4+ CD8- (Group 1

2019 International Journal of Dermatology

50. The impact of environmental ultraviolet exposure on the clinical course of mycosis fungoides. (Abstract)

The impact of environmental ultraviolet exposure on the clinical course of mycosis fungoides. As phototherapy plays an important role in the treatment of early-stage mycosis fungoides (MF), it is possible that environmental ultraviolet (UV) exposure affects the natural history of the disease.To assess the impact of environmental UV exposure on the clinical course of MF.The National Solar Radiation Database was used to identify the top and bottom registries for UV exposure from the Surveillance

2019 Journal of American Academy of Dermatology

51. Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version

Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer (...) Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: November 15, 2019. This PDQ cancer information summary has current information about the treatment of mycosis fungoides (including Sézary Syndrome). It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health

2017 PDQ - NCI's Comprehensive Cancer Database

52. New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. (Abstract)

New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. 30561000 2019 02 05 1365-2133 2018 Dec 18 The British journal of dermatology Br. J. Dermatol. New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. 10.1111/bjd.17533 Pileri A A https://orcid.org/0000-0002-1025-7171 Dermatology Unit, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Via Massarenti 1

2018 British Journal of Dermatology

53. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. Full Text available with Trip Pro

Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. Advanced age at diagnosis is considered a poor prognostic factor in mycosis fungoides (MF) and Sézary syndrome (SS).To evaluate the outcomes and prognostic factors in patients diagnosed at an advanced age (≥65 years) with MF/SS.Survival, progression rates and various clinical and histopathological variables were studied in a group of 174

2018 Journal of the European Academy of Dermatology and Venereology

54. Specific TCR gene rearrangements in mycosis fungoides: does advanced clinical stage show a preference? (Abstract)

Specific TCR gene rearrangements in mycosis fungoides: does advanced clinical stage show a preference? The relationship between the presence of specific T-cell receptor (TCR) gene rearrangements and clinical stage in mycosis fungoides (MF) has not been studied. We analysed a cohort of patients with a diagnosis of MF to determine the different types of specific TCR gene rearrangements present and their relationship to disease stage.A retrospective chart review was used to select patients

2018 Journal of Clinical Pathology

55. The PROCLIPI international registry of early stage Mycosis Fungoides identifies substantial diagnostic delay in most patients. Full Text available with Trip Pro

The PROCLIPI international registry of early stage Mycosis Fungoides identifies substantial diagnostic delay in most patients. Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete

2018 British Journal of Dermatology

56. Dramatic response to brentuximab vedotin in a refractory non-transformed CD30-negative mycosis fungoides allowing allogeneic stem cells transplantation and long-term complete remission. (Abstract)

Dramatic response to brentuximab vedotin in a refractory non-transformed CD30-negative mycosis fungoides allowing allogeneic stem cells transplantation and long-term complete remission. The erythrodermic ulcerated form of mycosis fungoides (MF) is exceptional, and treatment of refractory cases is challenging. Brentuximab vedotin (BV) is a monoclonal antibody combined with monomethyl auristatin E, recently approved for the treatment of refractory CD30+ cutaneous T-cell lymphoma. We report a case

2018 British Journal of Dermatology

57. Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pembrolizumab (...) in Treating Patients With Stage IB-IV Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03695471 Recruitment Status : Recruiting First Posted : October 4, 2018 Last Update Posted : January 3, 2019 See Sponsor

2018 Clinical Trials

58. Spiky follicular Mycosis Fungoides : A trichoscopic feature. (Abstract)

Spiky follicular Mycosis Fungoides : A trichoscopic feature. We have read with great interest a case report published by Slawinka et al describing trichoscopic spectrum of folliculotropic mycosis fungoides (FMF) [1]. Different trichoscopic aspects were reported by authors as the presence of milky white globules, yellow dots, short hair with split or triangle-shaped end, broken hair and pigtail appearance hair. This article is protected by copyright. All rights reserved.This article is protected

2018 Journal of the European Academy of Dermatology and Venereology

59. Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma. (Abstract)

Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma. 30298903 2019 02 04 1365-2133 180 2 2019 Feb The British journal of dermatology Br. J. Dermatol. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. 423-424 10.1111/bjd.17269 Deschamps O O http://orcid.org/0000-0003-0270-5920 Department of Dermatology, Hôpital Saint

2018 British Journal of Dermatology

60. Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution Full Text available with Trip Pro

Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution We aimed to evaluate clinical outcomes including progression-free survival (PFS), overall survival (OS), partial response, and complete response in patients who underwent radiation therapy (RT) for mycosis fungoides (MF). Also, we sought to find prognostic factors for clinical outcomes. Materials and.Total 19 patients confirmed with MF between 1999-2015 were

2018 Radiation oncology journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>